Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease

被引:155
作者
Kawada, Mayumi
Arihiro, Atsuko
Mizoguchi, Emiko
机构
[1] Massachusetts Gen Hosp, Harvard Med Sch, Gastrointestinal Unit, GRJ 702, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Harvard Med Sch, Boston, MA 02114 USA
关键词
inflammatory bowel disease; experimental colitis; dextran sodium sulfate; trinitrobenzene sulfonic acid; oxazolone; pathogenesis;
D O I
10.3748/wjg.v13.i42.5581
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Inflammatory bowel disease (IBD), the most important being Crohn's disease and ulcerative colitis, results from chronic dysregulation of the mucosal immune system in the gastrointestinal tract. Although the pathogenesis of IBD remains unclear, it is widely accepted that genetic, environmental, and immunological factors are involved. Recent studies suggest that intestinal epithelial defenses are important to prevent inflammation by protecting against microbial pathogens and oxidative stresses. To investigate the etiology of IBD, animal models of experimental colitis have been developed and are frequently used to evaluate new anti-inflammatory treatments for IBD. Several models of experimental colitis that demonstrate various pathophysiological aspects of the human disease have been described. In this manuscript, we review the characteristic features of IBD through a discussion of the various chemically induced experimental models of colitis (e.g. dextran sodium sulfate-, 2,4,6-trinitrobenzene sulfonic acid-, oxazolone-, acetic acid-, and indomethacin-induced models). We also summarize some regulatory and pathogenic factors demonstrated by these models that can, hopefully, be exploited to develop future therapeutic strategies against IBD. (c) 2007 WJG. All rights reserved.
引用
收藏
页码:5581 / 5593
页数:13
相关论文
共 187 条
[1]   Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease [J].
Abad, C ;
Martinez, C ;
Juarranz, MG ;
Arranz, A ;
Leceta, J ;
Delgado, M ;
Gomariz, RP .
GASTROENTEROLOGY, 2003, 124 (04) :961-971
[2]   Regulation of dextran sodium sulfate induced colitis by leukocyte beta 2 integrins [J].
Abdelbaqi, M ;
Chidlow, JH ;
Matthews, KM ;
Pavlick, KP ;
Barlow, SC ;
Linscott, AJ ;
Grisham, MB ;
Fowler, MR ;
Kevil, CG .
LABORATORY INVESTIGATION, 2006, 86 (04) :380-390
[3]   Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis:: Lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine [J].
Andres, PG ;
Beck, PL ;
Mizoguchi, E ;
Mizoguchi, A ;
Bhan, AK ;
Dawson, T ;
Kuziel, WA ;
Maeda, N ;
MacDermott, RP ;
Podolsky, DK ;
Reinecker, HC .
JOURNAL OF IMMUNOLOGY, 2000, 164 (12) :6303-6312
[4]   Involvement of interleukin-1 in the development of ulcerative colitis induced by dextran sulfate sodium in mice [J].
Arai, Y ;
Takanashi, H ;
Kitagawa, H ;
Okayasu, I .
CYTOKINE, 1998, 10 (11) :890-896
[5]   Effect of VIP on TLR2 and TLR4 expression in lymph node immune cells during TNBS-induced colitis [J].
Arranz, Alicia ;
Abad, Catalina ;
Juarranz, Yasmina ;
Torroba, Marta ;
Rosignoli, Florencia ;
Leceta, Javier ;
Perez Gomariz, Rosa ;
Martinez, Carmen .
VIP, PACAP, AND RELATED PEPTIDES: FROM GENE TO THERAPY, 2006, 1070 :129-134
[6]   Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation:: Evidence in Crohn disease and experimental colitis in vivo [J].
Atreya, R ;
Mudter, J ;
Finotto, S ;
Müllberg, J ;
Jostock, T ;
Wirtz, S ;
Schütz, M ;
Bartsch, B ;
Holtmann, M ;
Becker, C ;
Strand, D ;
Czaja, J ;
Schlaak, JF ;
Lehr, HA ;
Autschbach, F ;
Schürmann, G ;
Nishimoto, N ;
Yoshizaki, K ;
Ito, H ;
Kishimoto, T ;
Galle, PR ;
Rose-John, S ;
Neurath, MF .
NATURE MEDICINE, 2000, 6 (05) :583-588
[7]   Activation of PPAR γ and δ by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease [J].
Bassaganya-Riera, J ;
Reynolds, K ;
Martino-Catt, S ;
Cui, YZ ;
Hennighausen, L ;
Gonzalez, F ;
Rohrer, J ;
Benninghoff, AU ;
Hontecillas, R .
GASTROENTEROLOGY, 2004, 127 (03) :777-791
[8]   Growth factors in inflammatory bowel disease [J].
Beck, PL ;
Podolsky, DK .
INFLAMMATORY BOWEL DISEASES, 1999, 5 (01) :44-60
[9]   Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis [J].
Becker, Christoph ;
Dornhoff, Heike ;
Neufert, Clemens ;
Fantini, Massimo C. ;
Wirtz, Stefan ;
Huebner, Sabine ;
Nikolaev, Alexei ;
Lehr, Hans-Anton ;
Murphy, Andrew J. ;
Valenzuela, David M. ;
Yancopoulos, George D. ;
Galle, Peter R. ;
Karow, Margaret ;
Neurath, Markus F. .
JOURNAL OF IMMUNOLOGY, 2006, 177 (05) :2760-2764
[10]   Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor γ activity [J].
Berruyer, Carole ;
Pouyet, Laurent ;
Millet, Virginie ;
Martin, Florent M. ;
LeGoffic, Aude ;
Canonici, Alexandra ;
Garcia, Stephane ;
Bagnis, Claude ;
Naquet, Philippe ;
Galland, Franck .
JOURNAL OF EXPERIMENTAL MEDICINE, 2006, 203 (13) :2817-2827